James E. Levine

CIK: 0001463151

Transaction Breakdown

Open Market Buys (P)3 (60.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (40.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (2)

KZIA

KAZIA THERAPEUTICS LTD

Officer

CRDF

Cardiff Oncology, Inc.

Officer

Discretionary Trading P&L

Holdings

Transaction History (5 total)

KZIA
KAZIA THERAPEUTICS LTD
Jun 19, 2026
Award(A)
Employee Stock Option (right to buy)
Direct
200K shares-
CRDF
Cardiff Oncology, Inc.
Mar 11, 2025
Award(A)
Stock Options
Direct
332.6K shares-
CRDF
Cardiff Oncology, Inc.
Dec 18, 2024
Purchase(P)
Indirect
2.4K shares at avg. $5.00$12K
CRDF
Cardiff Oncology, Inc.
Dec 17, 2024
Purchase(P)
Indirect
2.8K shares at avg. $5.42$15K
CRDF
Cardiff Oncology, Inc.
Dec 16, 2024
Purchase(P)
Indirect
2.6K shares at avg. $3.83$10K

		Type	Shares	Price		Ownership
Jun 19, 2026	KZIA KAZIA THERAPEUTICS LTD	Award(A) Employee Stock Option (right to buy)	200,000	-	-	Direct
Mar 11, 2025	CRDF Cardiff Oncology, Inc.	Award(A) Stock Options	332,621	-	-	Direct
Dec 18, 2024	CRDF Cardiff Oncology, Inc.	Purchase(P)	2,400	$5.00	$12,000	Indirect
Dec 17, 2024	CRDF Cardiff Oncology, Inc.	Purchase(P)	2,752	$5.42	$14,905	Indirect
Dec 16, 2024	CRDF Cardiff Oncology, Inc.	Purchase(P)	2,564	$3.83	$9,820	Indirect

1-5 of 5 transactions

About Levine James E.

Levine James E. (SEC CIK 0001463151) files insider reports with the SEC as Chief Financial Officer of KAZIA THERAPEUTICS LTD (KZIA) and Chief Financial Officer of Cardiff Oncology, Inc. (CRDF).

Signal8 holds 4 ownership filings by Levine James E. (1 Form 3, 3 Form 4), filed between Dec 18, 2024 and Jun 23, 2026. Those filings report 5 transactions, from Dec 16, 2024 to Jun 19, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Levine James E.'s filings is in SYDNEY.

Recent filings by Levine James E.

Jun 19, 2026: Grant or award of KZIA derivative securities (Form 4, code A).
Mar 11, 2025: Grant or award of CRDF derivative securities (Form 4, code A).
Dec 18, 2024: Open-market purchase of CRDF shares (Form 4, code P).
Dec 17, 2024: Open-market purchase of CRDF shares (Form 4, code P).
Dec 16, 2024: Open-market purchase of CRDF shares (Form 4, code P).

Other insiders filing for KAZIA THERAPEUTICS LTD (KZIA)

Coffey Steven R. S., Director
Friend John E. II, Chief Executive Officer
Bonacorda Jeffrey, VP, Finance and Controller
Davidson Ebru, Director
Cain David, Director, CMC
APPLE ROBERT F, Director

How to read Form 4 transaction codes